Responders Vs. Non‐Responders or How to Predict the Response to GLP ‐1 or GLP ‐1/ GIP Receptor Agonist Therapy

医学 2型糖尿病 减肥 内科学 兴奋剂 超重 胰高血糖素样肽1受体 内分泌学 肥胖 生物信息学 肿瘤科 利拉鲁肽 叙述性评论 前瞻性队列研究 恶心 微生物群 糖尿病 社会心理的 受体 干呕 封锁 药物反应 呕吐
作者
Alina Kuryłowicz,Leszek Czupryniak
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:28 (12): 10950-10960 被引量:3
标识
DOI:10.1111/dom.71226
摘要

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists have transformed the pharmacological management of type 2 diabetes (T2D) and obesity, yet substantial interindividual variability in treatment response remains a defining clinical challenge. METHODS: Narrative review. PubMed was searched to 25 May 2026 (English language, human studies, 2005-2026) for biological, genetic, metabolic, hormonal, behavioural and psychosocial predictors of differential response. Evidence is organised across three clinically distinct contexts: glycaemic control in T2D; weight loss in people with overweight or obesity without T2D; and dual metabolic benefit in those with both conditions. RESULTS: Response heterogeneity is most pronounced in obesity without diabetes, where non-response-commonly defined as less than 5% total body weight loss-affects approximately 10% of participants in controlled trials, with real-world cohorts suggesting a higher frequency in routine practice; glycaemic non-response in T2D is less common but clinically significant. Across all three contexts, early on-treatment response is the most readily actionable predictor currently available. A recent large genome-wide association study reported associations between variation in the GLP1R drug-target gene and both weight-loss efficacy and gastrointestinal tolerability, and between agent-specific GIPR variants and nausea and vomiting with tirzepatide; these self-reported, single-cohort and as-yet unreplicated findings remain hypothesis-generating rather than a basis for individual-level genotyping. Metabolic, microbiome and neuroendocrine predictors are at a comparably preliminary stage. CONCLUSION: No single baseline characteristic reliably predicts response. Structured assessment of early on-treatment response is currently the most defensible basis for individualising therapy; genetic, metabolic and microbiome markers require prospective replication before clinical application.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
bmyy完成签到,获得积分10
刚刚
1秒前
策略发布了新的文献求助10
2秒前
2秒前
kaili完成签到 ,获得积分10
3秒前
兮兮完成签到,获得积分10
3秒前
科目三的应助被酷酷柚子采纳,获得10
4秒前
领导范儿的应助被生动易绿采纳,获得10
4秒前
4秒前
Condorzhang完成签到,获得积分10
4秒前
4秒前
5秒前
5秒前
蟹蟹发布了新的文献求助60
6秒前
dgb发布了新的文献求助10
6秒前
好好好发布了新的文献求助10
6秒前
斯文败类的应助被Zac采纳,获得10
7秒前
daomaihu发布了新的文献求助100
7秒前
朴实孤容发布了新的文献求助40
7秒前
duanhahaha完成签到,获得积分10
7秒前
Panda_Zhou完成签到,获得积分10
8秒前
JINYUBAO发布了新的文献求助10
9秒前
易义德发布了新的文献求助10
9秒前
10秒前
qq完成签到,获得积分10
10秒前
SHENGGE发布了新的文献求助10
12秒前
12秒前
慕青的应助被Ziezer采纳,获得10
12秒前
yy关闭了yy的文献求助
12秒前
13秒前
13秒前
13秒前
无极微光的应助被风来采纳,获得20
14秒前
李健的小迷弟的应助被老苍采纳,获得10
14秒前
Echo发布了新的文献求助10
14秒前
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178280
求助须知:如何正确求助?哪些是违规求助? 9569046
关于积分的说明 21802436
捐赠科研通 7773138
什么是DOI,文献DOI怎么找? 3432735
关于科研通互助平台的介绍 2556770
邀请新用户注册赠送积分活动 2478274